All In Biotech

Drug Trial Radar · NCT05389215

Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

102

Planned (sponsor's estimate)

Start

Jul 29, 2022

Primary completion

Oct 13, 2026

Study completion Jan 30, 2027

Sponsor

Sponsor type
Industry
First posted
May 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • DWN12088Drug

    DWN12088 Xmg Tablet (BID)

  • PlaceboDrug

    Placebo 0mg Tablet (BID)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of decline of FVCTime frame: From Day 1 through Week 24
  2. Incidents of treatment-emergent adverse eventsTime frame: From Day 1 through Week 24

Locations

30 sites in 2 countries. Site status is shown where the registry gives one.

  • Pulmonary Associates, PA

    Mesa, Arizona

  • Dignity Health Norton Thoracic Institute

    Phoenix, Arizona

  • The University of California San Francisco

    San Francisco, California

  • Loyola University Medical Center (LUMC)

    Maywood, Illinois

  • University of Kansas Medical Center Research Institute, Inc

    Kansas City, Kansas

  • Tufts Medical Center

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • University of Michigan Health System

    Michigan Center, Michigan

  • The Lung Research Center, LLC

    Chesterfield, Missouri

  • Duke University Medical Center

    Durham, North Carolina

  • Pulmonix Research, LLC

    Greensboro, North Carolina

  • Legacy Research Institute

    Portland, Oregon

  • Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • The U.S. Department of Veterans Affairs

    Charleston, South Carolina

  • Lowcountry Lung and Critical Care

    Charleston, South Carolina

  • Baylor Scott & White Research Institute

    Dallas, Texas

  • The University of Texas Southwestern Medical Center

    Dallas, Texas

  • Baylor College of Medicine

    Houston, Texas

  • The University of Texas Health San Antonio Medical Arts & Research Center

    San Antonio, Texas

  • Inje University Busan Paik Hospital

    Busan, Busan, South Korea

  • The Catholic University of Korea, Bucheon St. Mary's Hospital

    Bucheon-si, Gyeonggi-do, South Korea

  • Myongji Hospital

    Goyang-si, Gyeonggi-do, South Korea

  • Soon Chun Hyang University Hospital Bucheon

    Bucheon-si, Gyeonggido, South Korea

  • Ajou University Hospital

    Hwaseong-si, Gyeonggido, South Korea

  • Seoul National University Hospital

    Seoul, Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, Seoul, South Korea

  • Asan Medical Center

    Seoul, Seoul, South Korea

  • Samsung Medical Center

    Seoul, Seoul, South Korea

  • Ulsan University Hospital

    Ulsan, Ulsan, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.